BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche Diagnostics Corporation (ROG.VX) Breaks Ground on New $300 Million Learning and Development Center


11/14/2012 9:35:14 AM

INDIANAPOLIS, Nov. 14, 2012 /PRNewswire/ -- Mayor Greg Ballard today joined Roche Diagnostics President and CEO Jack Phillips as well as other Roche executives and community leaders to break ground on the company's new Learning and Development Center. The center is the first element of a $300 million site transformation investment that was announced in June 2012. The city of Indianapolis and the Indiana Economic Development Corporation offered Roche tax abatements, tax credits and training grants to support Roche's investment.

"Roche's decision to grow and invest in Indianapolis is a testament to our strength as a life sciences center," said Mayor Ballard, who participated in the ceremony held on the company's campus near the intersection of 96th Street and Interstate 69. "They've been an important part of our life sciences heritage for nearly 50 years now, and this expansion signals an important commitment to the region."

"Central Indiana has been our home since 1964 and we are here to stay," said Jack Phillips, president and CEO of Roche Diagnostics, adding that the company's history and growth in the region is due in part to the community's outstanding workforce and partnerships with the state and city that have enhanced job creation. 

The company, a leader in pharmaceuticals and diagnostics, will invest $300 million during the next 10 years at its North American headquarters on the northeast side of Indianapolis.  The capital investments will support the company's growing diagnostics and diabetes care businesses.  The new Learning and Development Center will host the training of more than 1,500 customers from across the nation each year. 

"It is fitting that the new Learning and Development Center is the first phase of our site transformation because it reflects our commitment to always put the customer first," said Phillips.

The ceremony also marked the first public unveiling of the new building's renderings, which when completed will be one of the most unique structures in Central Indiana. The center will employ a distinct architectural style consistent with the company's European heritage.

"As a key piece of our North American Headquarters, the new Learning and Development Center will serve as a hub and gateway for worldwide operations," said Phillips. "We felt that it was important for the building to reflect our global influence, right here in Indianapolis."

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Todd Siesky
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN
(317) 521-3966
todd.siesky@roche.com 

SOURCE Roche Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES